These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 11298060)

  • 1. The overactive bladder in children: a potential future indication for tolterodine.
    Hjälmås K; Hellström AL; Mogren K; Läckgren G; Stenberg A
    BJU Int; 2001 Apr; 87(6):569-74. PubMed ID: 11298060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder.
    Van Kerrebroeck P; Kreder K; Jonas U; Zinner N; Wein A;
    Urology; 2001 Mar; 57(3):414-21. PubMed ID: 11248608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients.
    Zinner NR; Mattiasson A; Stanton SL
    J Am Geriatr Soc; 2002 May; 50(5):799-807. PubMed ID: 12028164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial.
    Diokno AC; Appell RA; Sand PK; Dmochowski RR; Gburek BM; Klimberg IW; Kell SH;
    Mayo Clin Proc; 2003 Jun; 78(6):687-95. PubMed ID: 12934777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine.
    Appell RA; Abrams P; Drutz HP; Van Kerrebroeck PE; Millard R; Wein A
    World J Urol; 2001 Apr; 19(2):141-7. PubMed ID: 11374317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data.
    Larsson G; Hallén B; Nilvebrant L
    Urology; 1999 May; 53(5):990-8. PubMed ID: 10223495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial.
    Homma Y; Paick JS; Lee JG; Kawabe K;
    BJU Int; 2003 Nov; 92(7):741-7. PubMed ID: 14616458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolterodine use for symptoms of overactive bladder.
    Ruscin JM; Morgenstern NE
    Ann Pharmacother; 1999 Oct; 33(10):1073-82. PubMed ID: 10534221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder.
    Chapple CR; Rechberger T; Al-Shukri S; Meffan P; Everaert K; Huang M; Ridder A;
    BJU Int; 2004 Feb; 93(3):303-10. PubMed ID: 14764127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.
    Roehrborn CG; Abrams P; Rovner ES; Kaplan SA; Herschorn S; Guan Z
    BJU Int; 2006 May; 97(5):1003-6. PubMed ID: 16643482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study.
    Appell RA; Sand P; Dmochowski R; Anderson R; Zinner N; Lama D; Roach M; Miklos J; Saltzstein D; Boone T; Staskin DR; Albrecht D;
    Mayo Clin Proc; 2001 Apr; 76(4):358-63. PubMed ID: 11322350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder.
    Mattiasson A; Blaakaer J; Høye K; Wein AJ;
    BJU Int; 2003 Jan; 91(1):54-60. PubMed ID: 12614251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-ranging study of tolterodine in patients with detrusor hyperreflexia.
    Van Kerrebroeck PE; Amarenco G; Thüroff JW; Madersbacher HG; Lock MT; Messelink EJ; Soler JM
    Neurourol Urodyn; 1998; 17(5):499-512. PubMed ID: 9776013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of tolterodine with standard treatment in pediatric patients with non-neurogenic dysfunctional voiding/over active bladder: a systematic review.
    Medhi B; Mittal N; Bansal D; Prakash A; Sarangi SC; Nirthi B
    Indian J Physiol Pharmacol; 2013; 57(4):343-53. PubMed ID: 24968572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolterodine: as effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder.
    Lee JG; Hong JY; Choo MS; Kwon HY; Chung DY; Lee KS; Lee JY; Lee T
    Int J Urol; 2002 May; 9(5):247-52. PubMed ID: 12060436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study.
    Rentzhog L; Stanton SL; Cardozo L; Nelson E; Fall M; Abrams P
    Br J Urol; 1998 Jan; 81(1):42-8. PubMed ID: 9467475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolterodine: a safe and effective treatment for older patients with overactive bladder.
    Malone-Lee JG; Walsh JB; Maugourd MF
    J Am Geriatr Soc; 2001 Jun; 49(6):700-5. PubMed ID: 11454106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefit-risk assessment of tolterodine in the treatment of overactive bladder in adults.
    Garely AD; Burrows L
    Drug Saf; 2004; 27(13):1043-57. PubMed ID: 15471509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder.
    Jacquetin B; Wyndaele J
    Eur J Obstet Gynecol Reprod Biol; 2001 Sep; 98(1):97-102. PubMed ID: 11516807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
    Khullar V; Hill S; Laval KU; Schiøtz HA; Jonas U; Versi E
    Urology; 2004 Aug; 64(2):269-74; discussion 274-5. PubMed ID: 15302476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.